Senior Editor
Management of Type 1 and Type 2 diabetes is going high tech, thanks to a collaboration between Welldoc and Eli Lilly. The companies are partnering to integrate Welldoc's software into Lilly's connected insulin solutions, currently in development.
Under the terms of the agreement, Lilly and Welldoc will collaborate to create a new version of the BlueStar insulin management solution that integrates insulin dosing data for several Lilly insulins. Lilly will commercialize the pen platform, which will include the new app and Lilly's connected insulin pen solutions.
Welldoc's BlueStar app is a digital health solution cleared by the Food and Drug Administration for use by adults with Type 1 or Type 2 diabetes. The app has both prescription and non-prescription features such as insulin titration support, a bolus calculator and personalized health coaching, and integrates blood glucose monitoring and continuous glucose monitoring for people who use insulin.